Creating a new measure to assess early signs of psychosis in young people
Official title: DDT-COA-000-163 Accelerating the FDA COA Qualification Plan for the PSYCHS as a ClinRO measure
Funded at Yale University · NIH-10836892 · Data updated 2026-11-12
This study is working on a new tool called PSYCHS to help measure early signs of psychosis in young people, so that doctors can better understand how well treatments are working for those at risk.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project start | September 15, 2023 |
| Project end | June 30, 2025 |
| Funding year | 2023 |
| Award (this year) | $249,804 |
| NIH project number | 1U01FD008131-01 |
| Project ID | NIH-10836892 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are youth and young adults who exhibit early symptoms of psychosis, such as delusions or hallucinations.
✕Less likely to help
Patients who do not exhibit any symptoms of psychosis or are not at risk for developing psychosis may not benefit from this research.
What this research studies
This research focuses on developing a new clinical outcome assessment tool called the PSYCHS, which measures the severity of early symptoms of psychosis in youth and young adults. The goal is to create a qualification plan that will allow this tool to be recognized by the FDA, facilitating its use in future clinical trials aimed at finding effective treatments for individuals at high risk for psychosis. By harmonizing existing assessment instruments, the PSYCHS aims to provide a reliable way to evaluate treatment efficacy in this vulnerable population.
Why it matters
Potential benefit: If successful, this research could lead to the development of effective treatments for young individuals experiencing early signs of psychosis.
How similar studies have gone: Other research has shown success in developing clinical outcome measures for psychiatric conditions, indicating that this approach has potential.
Where this research is happening
-
Yale University
New Haven, United States Active
Researchers
- Principal investigator: Mourgues-Codern, Catalina Valerie — Yale University
- Study coordinator: Mourgues-Codern, Catalina Valerie
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.